Equillium (EQ) Long-Term Debt Issuances (2019 - 2023)

Equillium (EQ) posted quarterly Long-Term Debt Issuances of $7.7 million for Q2 2023, up 439.12% quarter-over-quarter from $1.4 million in Q1 2023.

Analysis

Equillium (EQ) Long-Term Debt Issuances (2019 - 2023) Analysis & Trends

Equillium (EQ) has reported Long-Term Debt Issuances for 2 consecutive years, with $7.7 million the latest figure, recorded in Q2 2023.

In Q2 2023, Long-Term Debt Issuances changed N/A year-over-year to $7.7 million; the TTM figure through Dec 2023 stood at $9.1 million (changed N/A YoY), while the FY2023 annual figure was $9.1 million, up 539.12% from the prior year.
Long-Term Debt Issuances grew to $7.7 million in Q2 2023 per EQ's latest filing, from $1.4 million in the prior quarter.
Across five years, Long-Term Debt Issuances topped out at $7.7 million in Q2 2023 and bottomed at -$60000.0 in Q4 2019.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	-
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	-
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	-
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	-
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	-
10	Equillium	249.33 Mn	249.33 Mn	-	-

Historic Data

Download Data